Mereo BioPharma (MREO) Accounts Payables (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Accounts Payables of $3.2 million for Q1 2026, up 10.33% year-over-year from $2.9 million in Q1 2025, and up 142.01% quarter-over-quarter from $1.3 million in Q4 2025.
Mereo BioPharma (MREO) Accounts Payables (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Accounts Payables for 10 consecutive years, with $3.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 10.33% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 10.33% YoY), while the FY2025 annual figure was $1.3 million, down 45.37% from the prior year.
- Accounts Payables improved to $3.2 million in Q1 2026 per MREO's latest filing, from $1.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $3.6 million in Q4 2022 and bottomed at $879000.0 in Q3 2025.
- Historically, Accounts Payables has averaged $2.4 million across 5 years, with a median of $2.4 million in 2024.
- On a YoY basis, Accounts Payables climbed as much as 19.1% in 2025 and fell as far as 57.85% in 2025.
- Mereo BioPharma's Accounts Payables stood at $3.6 million in 2022, then tumbled by 35.02% to $2.3 million in 2023, then gained by 4.01% to $2.4 million in 2024, then plunged by 45.37% to $1.3 million in 2025, then surged by 142.01% to $3.2 million in 2026.
- Business Quant data shows MREO's Accounts Payables at $3.2 million in Q1 2026, $1.3 million in Q4 2025, and $879000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.12 Mn |
| Mar 31, 2026 | 3.23 Mn |
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 879,000.00 |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Dec 31, 2023 | 2.35 Mn |
| Jun 30, 2023 | 2.39 Mn |
| Dec 31, 2022 | 3.61 Mn |
| Jun 30, 2022 | 3.55 Mn |
| Dec 31, 2021 | 3.37 Mn |
| Jun 30, 2021 | 3.06 Mn |
| Dec 31, 2020 | 4.40 Mn |
| Jun 30, 2020 | 6.82 Mn |
| Dec 31, 2019 | 8.17 Mn |
| Jun 30, 2019 | 8.69 Mn |